New insights from recurrent primary biliary cirrhosis in liver transplantation: The paradox of BEComing a fibroblast?

Hepatology

Volumn 45, Issue 4, 2007, Pages 837-840

  Wasilenko, Shawn ^a   Mason, Andrew L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; PHOSPHATIDYLINOSITOL 3 KINASE; PYRUVATE DEHYDROGENASE COMPLEX; TACROLIMUS; URSODEOXYCHOLIC ACID;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; DISEASE COURSE; EDITORIAL; EPITHELIUM CELL; FIBROBLAST; HUMAN; LIVER TRANSPLANTATION; MESENCHYME CELL; MORPHOGENESIS; OXIDATIVE PHOSPHORYLATION; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RECURRENT DISEASE;

EPITHELIAL CELLS; FIBROBLASTS; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; RECURRENCE;

EID: 34247394118     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21644     Document Type: Editorial

References (35)

1. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006;172:973-981.
2. Charatcharoenwitthaya P, Pimentel S, Talwalkar J, Enders F, Lindor K, Krom R, et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl, in press.
3. Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl 2005;11:1252-1257.
4. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. HEPATOLOGY 2001;33:22-27.
5. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl 2004;10:488-491.
6. Sanchez EQ, Levy MF, Goldstein RM, Fasola CG, Tillery GW, Netto GJ, et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation 2003;76: 1583-1588.
7. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142.
8. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003;15:740-746.
9. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784.
10. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443-7454.
11. Xia JL, Dai C, Michalopoulos GK, Liu Y. Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation. Am J Pathol 2006;168: 1500-1512.
12. Rygiel K, Robertson H, Burt A, Jones D, Kirby J. Demonstration of the transition of intrahepatic biliary epithelial cells to fibroblasts during chronic inflammatory liver diseases [Abstract]. J Hepatol 2006;45: s241.
13. Alvaro D, Invernizzi P, Onori P, Franchitto A, De Santis A, Crosignani A, et al. Estrogen receptors in cholangiocytes and the progression of primary biliary cirrhosis. J Hepatol 2004;41:905-912.
14. Onori P, Alvaro D, Floreani A, Mancino M, Franchitto A, Guido M, et al. Activation of IGF1 system characterizes cholangiocyte survival during the progression of primary biliary cirrhosis (PBC). J Histochem Cytochem 2006;December 12, advance online publication.
15. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003;63:2172-2178.
16. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-480.
17. Ober EA, Verkade H, Field HA, Stainier DY. Mesodermal Wnt2b signalling positively regulates liver specification. Nature 2006;442:688-691.
18. Zeng G, Awan F, Otruba W, Mullet P, Apte U, Tan X, et al. Wnt'er in liver: expression of Wnt and frizzled genes in mouse. HEPATOLOGY 2007; 45:195-204.
19. Tan X, Behari J, Cieply B, Michalopoulos GK, Monga SP. Conditional deletion of beta-catenin reveals its role in liver growth and regeneration. Gastroenterology 2006;131:1561-1572.
20. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression. Gut 2001;49:565-576.
21. Nusse R, van Ooyen A, Cox D, Fung YK, Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 1984;307:131-136.
22. Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A 2003;100:8454-8459.
23. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005;24:7435-7442.
24. Warburg O. The Metabolism of Tumors. Constable and Company, Ltd. London. 1930:327.
25. Yang YC, Piek E, Zavadil J, Liang D, Xie D, Heyer J, et al. Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci U S A 2003;100:10269-10274.
26. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005;24:5764-5774.
27. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793-d807.
28. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, et al. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003;125:178-191.
29. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA, Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. HEPATOLOGY 2001;34:89-100.
30. Shek FW, Benyon RC. How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 2004; 16:123-126.
31. Saperstein LA, Jirtle RL, Farouk M, Thompson HJ, Chung KS, Meyers WC. Transforming growth factor-beta 1 and mannose 6-phosphate/insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fibrosis in the rat. HEPATOLOGY 1994;19:412-417.
32. Holterman AX, Tan Y, Kim W, Yoo KW, Costa RH. Diminished hepatic expression of the HNF-6 transcription factor during bile duct obstruction. HEPATOLOGY 2002;35:1392-1399.
33. Lombard M, Portmann B, Neuberger J, Williams R, Tygstrup N, Ranek L, et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993;104:519-526.
34. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003;9(Suppl):S1-S9.
35. Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-122.